![Catia Neto](https://profiles-cardiff.imgix.net/attachments/2906?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Catia Neto
(she/her)
- Available for postgraduate supervision
Teams and roles for Catia Neto
Overview
I joined Cardiff University as a PhD student in 2016 and was appointed Lecturer in 2024.
My research focuses on neuro-oncology and tumour immunology, with a particular emphasis on using iPSC-derived models to study glioblastoma and its interactions with the immune microenvironment. I am currently extending this work into renal biology through a project developing iPSC-derived proximal tubule kidney organoids. The aim of my research is to establish human-relevant platforms that improve our understanding of disease mechanisms and inform the development of new therapies.
Alongside my research, I am building my lab and supervising PhD and MSc students. I contribute to teaching across the MPharm, Medical Pharmacology (BSc), and MSc programmes in Cancer Biology and Therapeutics and Clinical Research, as well as supervising theses in related areas. I am committed to translational science, interdisciplinary collaboration, and mentoring the next generation of researchers and healthcare scientists.
Publication
2021
- Moriconi, C., Civita, P., Neto, C., Pilkington, G. J. and Gumbleton, M. 2021. Caveolin-1, a key mediator across multiple pathways in glioblastoma and an independent negative biomarker of patient survival. Frontiers in Oncology 11, article number: 701933. (10.3389/fonc.2021.701933)
- Singh, B. et al. 2021. Towards more predictive, physiological and animal-free in vitro models: advances in cell and tissue culture 2020 conference proceedings. Alternatives to Laboratory Animals 49(3), pp. 93-110. (10.1177/02611929211025006)
- Das Neves Neto, C. 2021. Role of Caveolin-1 in microglial phenotype: impact on Glioblastoma. PhD Thesis, Cardiff University.
2020
- Alghamdi, M. et al. 2020. Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme. Nanoscale Advances 2(10), pp. 4498-4509. (10.1039/D0NA00471E)
- Schirmer, L. et al. 2020. Heparin-based, injectable microcarriers for controlled delivery of interleukin-13 to the brain. Biomaterials Science 8(18), pp. 4997-5004. (10.1039/D0BM01249A)
- Leite, D. M., Zvar Baskovic, B., Civita, P., Neto, C., Gumbleton, M. and Pilkington, G. J. 2020. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. The FASEB Journal 34(1), pp. 1710-1727. (10.1096/fj.201901858RR)
Erthyglau
- Moriconi, C., Civita, P., Neto, C., Pilkington, G. J. and Gumbleton, M. 2021. Caveolin-1, a key mediator across multiple pathways in glioblastoma and an independent negative biomarker of patient survival. Frontiers in Oncology 11, article number: 701933. (10.3389/fonc.2021.701933)
- Singh, B. et al. 2021. Towards more predictive, physiological and animal-free in vitro models: advances in cell and tissue culture 2020 conference proceedings. Alternatives to Laboratory Animals 49(3), pp. 93-110. (10.1177/02611929211025006)
- Alghamdi, M. et al. 2020. Poly(ethylene glycol) based nanotubes for tuneable drug delivery to glioblastoma multiforme. Nanoscale Advances 2(10), pp. 4498-4509. (10.1039/D0NA00471E)
- Schirmer, L. et al. 2020. Heparin-based, injectable microcarriers for controlled delivery of interleukin-13 to the brain. Biomaterials Science 8(18), pp. 4997-5004. (10.1039/D0BM01249A)
- Leite, D. M., Zvar Baskovic, B., Civita, P., Neto, C., Gumbleton, M. and Pilkington, G. J. 2020. A human co-culture cell model incorporating microglia supports glioblastoma growth and migration, and confers resistance to cytotoxics. The FASEB Journal 34(1), pp. 1710-1727. (10.1096/fj.201901858RR)
Gosodiad
- Das Neves Neto, C. 2021. Role of Caveolin-1 in microglial phenotype: impact on Glioblastoma. PhD Thesis, Cardiff University.
Research
We use induced pluripotent stem cell (iPSC)-derived models to study complex cellular interactions within disease microenvironments, aiming to develop human-relevant platforms to study disease biology and inform therapeutic development.
Research Areas
- Glioblastoma and tumour-immune interactions. Our lab investigate how immune cells, microglia, macrophages and T-cells, interact with glioblastoma cells within the brain tumour microenvironment.
- Kidney Organoid development. We are uisng iPSC-derived proximal tubule cell (PTC) kidney organoids to model renal biology and disease.
Teaching
MPharm:
-
PH3113: Drugs and Diseases 2
-
PH4116: Pharmacy Research or Scholarship Project (supervision)
-
OSCE examination marker
Medical Pharmacology (BSc):
-
PH2561: Principles of Neuropharmacology
Cancer Biology and Therapeutics (MSc):
-
PHT801: Cellular and Molecular Biology of Cancer
-
PHT802: Translational Oncology and Therapeutics
-
PHT804: Laboratory Research Skills
-
PHT805: Research Project (supervision)
Biography
I am a Lecturer (Teaching and Research) in Pharmaceutical & Health Technologies at School of Pharmacy and Pharmaceutical Sciences. My research focuses on the intersection of neuroscience, oncology, immunology, and stem cell technologies, with a particular interest in modelling diseases and exploring translational approaches for therapeutic development.
I joined Cardiff University in 2016 as a PhD student, where I studied the role of Cav1 in microglial phenotype and glioblastoma. I continued as a Postdoctoral Research Associate (2021–2024), co-leading a project on iPSC-derived brain organoids and microglia–glioma interactions. In 2024, I was appointed Lecturer to further develop research at the interface of cancer biology and immunotherapy, and human-relevant models.
Prior to moving to the UK, I worked as a Research Associate and Nuclear Medicine Technologist at ICNAS, University of Coimbra, Portugal. I hold an MSc in Molecular Medicine and Oncology (University of Porto) and a BSc in Nuclear Medicine (Polytechnic Institute of Porto).
My work is driven by a commitment to translational science and collaboration, bridging fundamental biology and clinical application.
